financetom
Business
financetom
/
Business
/
Linda Yaccarino, CEO of Elon Musk's X, to step down in surprise move
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Linda Yaccarino, CEO of Elon Musk's X, to step down in surprise move
Jul 9, 2025 8:33 AM

July 9 (Reuters) - Elon Musk-owned social platform X's

CEO Linda Yaccarino said on Wednesday she would step down from

the role in a surprise move.

Her exit comes at a difficult time for Musk, who is dealing

with falling sales at his EV maker Tesla and is embroiled in a

war of words with U.S. President Donald Trump.

Yaccarino did not give a specific reason for her decision.

X and Yaccarino did not immediately respond to requests for

comment.

She took the top job in 2023 to help Musk transform the

company after he bought it in a $44 billion deal.

Prior to becoming the CEO of X, Yaccarino spent several

years modernizing the ad business of Comcast's NBCUniversal.

The social media platform is dealing with a heavy debt load,

and Yaccarino has had to often deal with controversies stirred

up by Musk, including his endorsement of antisemitic conspiracy

theories in late 2023.

The company later sued numerous advertisers and an

advertising group, alleging they colluded to deny X ad dollars.

In March, Musk's AI startup xAI acquired the social media

platform in a $33 billion all-stock deal.

Its chatbot Grok removed what it called "inappropriate"

social media posts on Tuesday after complaints from X users and

the Anti-Defamation League that Grok produced content with

antisemitic tropes.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Zevra Therapeutics prices genetic disorder drug at up to $106,000 per month
Zevra Therapeutics prices genetic disorder drug at up to $106,000 per month
Oct 3, 2024
Sept 23 (Reuters) - Zevra Therapeutics' ( ZVRA ) drug, Miplyffa, for treating a rare and fatal genetic disorder will have a wholesale acquisition cost ranging between $40,000 and $106,000 per month depending on dosage, the company said on a conference call on Monday. The U.S. health regulator on Friday approved the drug making it the first treatment to get...
Market Chatter: Xiaomi Asks Indian Watchdog to Recall Antitrust Report on Walmart India Unit Flipkart
Market Chatter: Xiaomi Asks Indian Watchdog to Recall Antitrust Report on Walmart India Unit Flipkart
Oct 3, 2024
08:29 AM EDT, 09/23/2024 (MT Newswires) -- Chinese smartphone maker Xiaomi has asked the Competition Commission of India to recall its antitrust report, which found Xiaomi and Walmart's ( WMT ) India unit Flipkart in breach of competition laws, Reuters reported Monday, citing people familiar with the matter. Any recall of the commission's report could cause a delay in its...
Ventyx Biosciences Shares Up as Sanofi to Invest $27 Million
Ventyx Biosciences Shares Up as Sanofi to Invest $27 Million
Oct 3, 2024
08:25 AM EDT, 09/23/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) shares were up 25% in recent Monday premarket activity after announcing it will receive a $27 million investment from Sanofi ( SNY ) . Sanofi ( SNY ) agreed to purchase 70,601 of the Company's Series A non-voting convertible preferred shares, each initially convertible into 100 shares, Ventyx...
Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Monday Ahead of Key Inflation Data
Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Monday Ahead of Key Inflation Data
Oct 3, 2024
08:27 AM EDT, 09/23/2024 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust ( SPY ) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Monday's premarket activity, ahead of a key inflation data release due later in the week. US stock futures were also edging higher, with S&P 500...
Copyright 2023-2026 - www.financetom.com All Rights Reserved